Antibody-Drug Conjugate (ADC) Drug Landscape: Historical, Current, and Emerging Therapies
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report investigates the impacts and development of Antibody-Drug Conjugate therapies within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes within the market and how best to pivot to prioritize future changes in the market.
Scope
This 53-page report gives important, expert insight you won’t find in any other source. 28 figures throughout the report illustrate major points and trends within the Antibody- Drug Conjugate market delving deep into forecasted sales and company pipelines. This report is required reading for –
Investors that want to understand past trends impacting the Antibody- Drug Conjugate landscape as well as identifying companies to invest in
Companies that are interested in entering the Antibody- Drug Conjugate landscape and where best to focus on
Large pharma companies with investment groups or BD teams looking to see which companies lead the Antibody- Drug Conjugate landscape in the past and how they led
Small and medium pharma who want to focus their Antibody- Drug Conjugate drug portfolio on future trends and are looking for partnership opportunities
Reasons to Buy
Insights on the different types of Antibody- Drug Conjugate with current and novel forms
Insights on past trends and changes that have informed the Antibody- Drug Conjugate market
Insights on the current leading Antibody- Drug Conjugate drugs based on their Sales and Forecasts and other parameters
Therapeutic and Indication insights into the Antibody- Drug Conjugate market
Insights into the future opportunities for Antibody- Drug Conjugate and the companies leading in the market.
Seagen
F. Hoffmann-La Roche Ltd
Roche Holding AG
Daiichi-Sankyo Co Ltd
Abbvie Inc
Pfizer Inc
Regeneron Pharmaceuticals Inc
Gilead Sciences
Novartis AG
Bristol Myers Squibb Co
Astrazeneca Plc
Sanofi
Biocytogen Pharmaceutical Co Ltd
Hangzhou DAC Biotech Co Ltd
LigaChem Biosciences Inc
Innovent Biologics Inc
Shanghai Affinity Biopharmaceutical Co Ltd
LaNova Medicines Ltd
Genmab AS
Jiagsu Hengrui Pharmaceuticals Co Ltd
Duality Biologics Co Ltd
BioNTech SE
Remegen Co Ltd
CSPC Pharmaceutical Group Ltd
Zai Lab
Cytomx Therapeytics Inc
GSK Plc
Primelink Biotherapeutics Co Ltd
Radiopharam Theranostics
T-E Meds Inc
Neok Bio Inc
National Cancer Institute US
Hutchmed China Ltd
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports